N,N'-bis(perhydroazepine) | 67523-79-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: N,N'-bis(perhydroazepine)
• 英文别名: 1,1'-biperhydroazepine；azabicycloheptane；Biazepan；1-(azepan-1-yl)azepane
• CAS: 67523-79-9
• 化学式: C₁₂H₂₄N₂
• 分子量: 196.336
• InChiKey: DIZDXNWGCKCZDS-UHFFFAOYSA-N

物化性质

• 沸点：
  287.1±23.0 °C(Predicted)
• 密度：
  0.961±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  环己亚胺 在 sodium hydroxide 、 sodium persulfate 、 silver nitrate 作用下， 以 ammonium hydroxide 、 水 为溶剂， 反应 17.0h， 以0.3%的产率得到N,N'-bis(perhydroazepine)
  参考文献：
  名称：

  Ogawa, Keiichiro; Nomura, Yujiro; Takeuchi, Yoshito, Journal of the Chemical Society. Perkin transactions I, 1982, # 12, p. 3031 - 3036

  摘要：

  DOI：

文献信息

• Drug conjugates
  申请人：Ojima Iwao

  公开号：US20050232928A1

  公开（公告）日：2005-10-20

  A compound having the formula Y-A-Z, wherein: A is a 5, 6, or 7 member ring that is monocyclic or is fused to 1 to 3 additional 4 to 8 member rings; wherein ring A and, independently, the fused additional rings are carbocyclic or heterocyclic, and saturated or unsaturated, wherein unsaturated rings are aromatic or non-aromatic; wherein Y and Z are substituents at adjacent positions on ring A; Y represents: Z represents: X and E represent O, S, or NR a or NR b ; each of a, b, c, d, e and f independently represents 0 or 1; a+c equals 0, 1, or 2; b+d equals 0, 1, or 2; a+b+c+d+e+f equals 1, 2, or 3; provided that when f is 1, then d is 1, and when d is 0, then f is 0; and when both e and b are 0, then neither R 1 nor R 1 is chloro or bromo; v represents 0 or 1, provided that when v is 0, then J is hydrogen, a metal ion, or a quaternary ammonium ion; and X is O and G is H; either G is hydrogen, a metal ion, a quaternary ammonium ion, lower alkyl, or comprised of a pharmaceutically active chemical compound or the precursor thereof; or X-G represents a carbonyl-activating group; J is lower alkyl, aryl, heteroaryl, omega-hydroxycarbonyl-(lower alkyl), omega-(lower alkoxy)carbonyl-(lower alkyl), omega-(X-G)-carbonyl-(lower alkyl) group, or comprised of a specific binding agent; and R a , R b , R 1 , R 2 , R 3 , R 4 are as defined in the specification.

  具有Y-A-Z分子式的化合物，其中：A是一个5、6或7成员环，可以是单环的，也可以与1至3个额外的4至8成员环融合；其中环A和额外融合的环独立地可以是碳环或杂环，饱和或不饱和，不饱和环可以是芳香的或非芳香的；其中Y和Z是环A上相邻位置的取代基；Y代表：Z代表：X和E代表O、S或NRa或NRb；a、b、c、d、e和f中的每一个独立地代表0或1；a+c等于0、1或2；b+d等于0、1或2；a+b+c+d+e+f等于1、2或3；条件是当f为1时，d为1，当d为0时，f为0；当e和b都为0时，R1和R1都不是氯或溴；v代表0或1，条件是当v为0时，J为氢、金属离子或季铵离子；X为O且G为H；G为氢、金属离子、季铵离子、低碳基，或由药用活性化学化合物或其前体组成；或者X-G代表一个羰基活化基团；J为低碳基、芳基、杂环基、ω-羟基羰基-(低碳基)、ω-(低烷氧基)羰基-(低碳基)、ω-(X-G)-羰基-(低碳基)基团，或由特异结合剂组成；而Ra、Rb、R1、R2、R3、R4如规范中所定义。
• ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES
  申请人：Prince B. Ryan

  公开号：US20070259907A1

  公开（公告）日：2007-11-08

  Thiazoloquinoline and thiazolonaphthyridine compounds having an aryl or arylalkylenyl substituent at the 6-, 7-, 8-, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

  本发明公开了在6、7、8或9位具有芳基或芳基烷基取代基的噻唑喹啉和噻唑萘啶化合物、含有该化合物的制药组合物、中间体以及这些化合物作为免疫调节剂、用于调节动物细胞因子生物合成以及治疗包括病毒和肿瘤疾病的方法。
• Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
  申请人：Kshirsagar A. Tushar

  公开号：US20080015184A1

  公开（公告）日：2008-01-17

  Imidazopyridine, imidazoquinoline, and imidazonaphthyridine compounds having a urea substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

  本发明涉及在2-位具有脲基的咪唑吡啶，咪唑喹啉和咪唑萘啶化合物，含有这些化合物的药物组合物，中间体以及这些化合物的制备方法和使用方法，作为免疫调节剂，在动物中调节细胞因子生物合成，并用于治疗包括病毒和肿瘤疾病在内的疾病。
• Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods
  申请人：Lundquist, JR. Gregory D.

  公开号：US20100240693A1

  公开（公告）日：2010-09-23

  Thiazolo[ 4,5 -c]ring compounds, (e.g. thiazolopyridine, thiazoloquinoline, 6,7,8,9 -tetrahydrothiazoloquinoline, thiazolonaphthyridine, and 6,7,8,9 -tetrahydrothiazolonaphthyridine compounds) having an oxime or hydroxylamine substituent at the 2 -position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

  本发明涉及一种噻唑并[4,5-c]环化合物（例如噻唑吡啶、噻唑喹啉、6,7,8,9-四氢噻唑喹啉、噻唑萘啉和6,7,8,9-四氢噻唑萘啉化合物），其在2位具有肟或羟肟取代基，以及含有该化合物的制药组合物、中间体、制备方法和用于免疫调节剂、调节动物细胞因子生物合成以及治疗包括病毒和肿瘤疾病的方法。
• HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS
  申请人：Dellaria, JR. Joseph F.

  公开号：US20100152230A1

  公开（公告）日：2010-06-17

  Hydroxy substituted 1H-imidazo[4,5-c]pyridin-4-amines, with a hydroxy substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

  本发明公开了具有羟基取代的1H-咪唑[4,5-c]吡啶-4-胺类化合物，其中在2-位的位置有羟基取代基，以及包含这些化合物的药物组合物，制备这些化合物的方法，中间体以及这些化合物用作免疫调节剂的使用方法，用于在动物体内诱导细胞因子生物合成以及用于治疗病毒和肿瘤性疾病。